New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

Novo Nordisk tells staff to return to office

At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate ...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

New diagnostic rules raise concerns

In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagno...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

Gene therapy restored hearing in children with congenital deafness

Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Enkelt test kan förutsäga leversjukdom - ”Bygger på tre enkla blodprover”

Ett blodtest, utvecklat av forskare vid Karolinska institutet, kan förutsäga risken att utveckla allvarlig leversjukdom, enligt en ny studie

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

Will the FDA’s new transparency policy extend to medical devices? (Part 1)

, it may signal what’s ahead for medical devices.

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...